Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This study is testing a new cell therapy that targets two proteins at once — CD19 and CD20 — in people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or not responded to initial treatment. This dual-targeting approach may help the therapy be more effective even if cancer cells lose one of the two targets. **You may be eligible if...** - You are aged 18 to 75 years old - You have confirmed B-cell non-Hodgkin lymphoma that expresses CD19 and/or CD20 - Your cancer did not respond to first-line treatment, or it came back within 12 months of achieving complete remission - You are not suitable for, or not willing to receive, standard CAR-T cell therapy - You are in good general health (ECOG 0 or 1) - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - You have another active invasive cancer - You have active graft-versus-host disease (a complication after bone marrow transplant) or need immune-suppressing treatment for it - Your lymphoma has actively spread to the brain or spinal fluid - You have significant bleeding problems or are taking long-term steroids or immune suppressants - You are breastfeeding Talk to your doctor to see if this trial is right for you.